• Thurs news: Novo Nordisk’s port strike distribution plan. Arcus/AZ renal cancer trial. Lilly weight loss drugs no longer in shortage. Difficulties of a CVS breakup. Google and Biontech AI lab assistants. See more on our front page

Thanks for not posting RX weeklies













Symphony VPak numbers for w/e 6/5; TRx@ 871 & NRx@ 495
TRx is -9% compared to its high 955 reported w/e 5/22
NRx is -8% compared to its high 536 reported w/e 4/3

Gilead Benchmark
Symphony Harvoni/Solvaldi numbers for w/e 6/5; TRx@ 11,437 & NRx@ 5,057

BE INSPIRED.... WERE GETTING CLOSER TO THE 51% TARGET !!!
AWESOME PROGRESS 6 MONTHS INTO LAUNCH....
 




Symphony VPak numbers for w/e 6/5; TRx@ 871 & NRx@ 495
TRx is -9% compared to its high 955 reported w/e 5/22
NRx is -8% compared to its high 536 reported w/e 4/3

Gilead Benchmark
Symphony Harvoni/Solvaldi numbers for w/e 6/5; TRx@ 11,437 & NRx@ 5,057

BE INSPIRED.... WERE GETTING CLOSER TO THE 51% TARGET !!!
AWESOME PROGRESS 6 MONTHS INTO LAUNCH....

Maybe Ricky should be working on rebuilding this company's pipeline instead of pretending to rebuild a house.
 




Symphony VPak numbers for w/e 6/5; TRx@ 871 & NRx@ 495
TRx is -9% compared to its high 955 reported w/e 5/22
NRx is -8% compared to its high 536 reported w/e 4/3

Gilead Benchmark
Symphony Harvoni/Solvaldi numbers for w/e 6/5; TRx@ 11,437 & NRx@ 5,057

BE INSPIRED.... WERE GETTING CLOSER TO THE 51% TARGET !!!
AWESOME PROGRESS 6 MONTHS INTO LAUNCH....

OMG!! WTF!! Fire HQ!!! F' em!! Pitiful!! FCF!! KMA!!
 




Symphony VPak numbers for w/e 6/5; TRx@ 871 & NRx@ 495
TRx is -9% compared to its high 955 reported w/e 5/22
NRx is -8% compared to its high 536 reported w/e 4/3

Gilead Benchmark
Symphony Harvoni/Solvaldi numbers for w/e 6/5; TRx@ 11,437 & NRx@ 5,057

BE INSPIRED.... WERE GETTING CLOSER TO THE 51% TARGET !!!
AWESOME PROGRESS 6 MONTHS INTO LAUNCH....

Look on the positive side, we're close to 7.5% in global sales, a gain of 3% since 1q15. If we continue to gain 3%/ quarter, we'll get to 51% within 4 years.

Unless Merck's HCV one tablet treatment steals market share, to be launched later this year.
 




The awful Rx performance of VPak is sickening. I remember an analyst's call where little Ricky said a few more pills a day won't impact the uptake of VPak versus Harvoni! That prediction is enough for the Board to kick him out! The past performance record of Lootsie is less than stellar and in fact, is replete with market share failures!! Louie Louie is clueless and nods to everything Lootsie spouts. The only DM worth anything is Melissa!! It is time for our company to say adios to HCV and pray for success in oncology!!
 
























What is the talk I am hearing of a re-launch campaign coming up after July 4? I heard this from a vendor who swab test for Hep C (among other dangerous infections).

Excellent! As long as they've eliminated RBV, DDI's, BID dosing, and contracted with managed care for exclusivity it should be a resounding success. Can't wait.
 




























Similar threads

Replies
1
Views
808
AbbVie
anonymous
Replies
11
Views
3K
AbbVie
Anonymous
Replies
42
Views
6K
AbbVie
Anonymous
Replies
16
Views
4K
AbbVie
Anonymous